Non-Alcoholic Steatohepatitis (NASH) Market Revenue Growth by 2025

Posted by Sandeep Salunkhe on March 8th, 2019

Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market.

However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market. At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH.

Download sample copy @ https://www.alliedmarketresearch.com/request-sample/224

According to Allied Market Research, the global non-alcoholic steatohepatitis (NASH) market was valued at ,179 million in 2017, and is expected to reach ,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world.

However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

Snapshot of Asia-Pacific non-alcoholic steatohepatitis (NASH) industry  

Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific. Some other factors such as developing healthcare infrastructure, emerging economies, and growing rate of diagnosis are further expected to support the growth of the non-alcoholic steatohepatitis (NASH) market in Asia-Pacific. Moreover, increase in healthcare awareness in the emerging economies such as India and China further fuel the growth of the market.

 Key Findings:

• Based on drug type, the selonsertib & cenicriviroc segment is expected to exhibit the fastest market growth, is projected to grow at a CAGR of 73.7% from 2021 to 2025.
• Based on sales channel, the retail pharmacy segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• Based on sales channel, the online provider segment exhibited fastest growth and is anticipated to grow at a CAGR of 63.2% from 2021-2025.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 62.62% during the forecast period.

Send enquiry us @ https://www.alliedmarketresearch.com/purchase-enquiry/224